Diasorin

A multiplexed in-vitro diagnostic test for the detection and identification of 19 viral pathogens including SARS-CoV-2, and two bacterial pathogens from extracted nucleic acid samples in a single well, enabling thorough respiratory health analysis.

A multiplex, real-time PCR-based test that qualitatively detects nucleic acid from 2 bacterial and 20 viral respiratory pathogens, including SARS-CoV-2, from nasopharyngeal swab samples.

A qualitative, multiplexed molecular test for the simultaneous detection and identification of up to 24 bacterial, viral, and parasitic targets with the flexibility to only test and pay for what is clinically relevant.

Positive control pack for the Simplexa COVID-19 & Flu A/B Direct kit, used for quality control in diagnostic testing.

A multiplex real-time sample-to-answer PCR test for detection and differentiation of SARS-CoV-2, influenza A, influenza B, and RSV in nasopharyngeal swabs from individuals with respiratory tract infection symptoms.

For the quantitative determination of SARS-CoV-2 nucleocapsid protein antigen in nasal swab (NS), nasopharyngeal swab (NPS), in individuals suspected to have COVID-19 by their healthcare provider within the first ten days from the onset of symptoms and in nasopharyngeal swab (NPS) in asymptomatic subjects.

Immunoassay analyzer designed for large laboratories combining high throughput and high sensitivity within a powerful and fully automated system that can seamlessly connect to facilitate Total Laboratory Automation.

For the quantitative determination of anti-trimeric spike protein specific IgG antibodies to SARS-CoV-2 in human serum or plasma samples.

The VERIGENE System is a sample-to-answer molecular diagnostic platform that rapidly identifies pathogens responsible for infectious diseases, including bloodstream, respiratory, and gastrointestinal infections. It offers automated sample preparation and test processing with minimal hands-on time and flexible assay options including PCR and direct DNA detection.

A high-performance standalone COVID-19 testing assay used during pandemic peaks, providing simple utility and reliable results.

A multiplex assay for rapid and accurate detection and differentiation of SARS-CoV-2, influenza A, influenza B, and RSV directly from nasopharyngeal and anterior nasal swabs, providing critical diagnostic support in a single streamlined test.

A molecular multiplex panel that detects 21 different pathogens (bacteria and viruses), including SARS-CoV-2, designed for high throughput laboratories with ready-to-use lyophilized reagent wells.

A point of care, real-time RT-PCR test used on the patented LIAISON NES instrument to detect influenza A, influenza B, RSV, and SARS-CoV-2 viruses in dry nasal swabs in approximately 15 minutes.

A real-time RT-PCR assay run on LIAISON® MDX to detect Flu A, Flu B & RSV in one sample with a simple sample-to-answer workflow and no RNA extraction needed.

A 21-target syndromic panel for comprehensive and customizable Flex Testing in complex or immunocompromised cases.

A sample-to-answer assay for detection and differentiation of influenza A/B and RSV with broad strain coverage.

The first commercial test that allows the user to choose any combination of 16 viral and bacterial targets for an individual sample at the time of test ordering, based on the clinician and patient’s needs, paying only for the targets reported. It offers a flexible respiratory pathogen testing algorithm that addresses clinician and patient needs while minimizing financial and resource burden on the laboratory.

A flexible, multiplexed respiratory panel for syndromic testing that identifies the most common respiratory pathogens with the flexibility to pay for only selected pathogens within the comprehensive panel.

A real-time RT-PCR assay run on the LIAISON NES® instrument to detect influenza A, influenza B, respiratory syncytial virus, and SARS-CoV-2 from a single nasal swab sample in approximately 15 minutes, enabling rapid and accurate respiratory pathogen detection for timely diagnosis and treatment.

Positive control pack for Simplexa® Flu A/B & RSV Direct assay, used for quality control in diagnostic testing.

Positive control pack for the Simplexa® Bordetella Direct assay, used to ensure assay performance and accuracy.

An assay that differentiates key Bordetella species (B. pertussis and B. parapertussis) in pertussis-suspected patients in about 1 hour, ideal for outbreak-related testing.